rethinkTHC Search
Menu
Study breakdown

Cannabis Use Disorder in MS Patients Is Common but Treatment Options Are Nearly Nonexistent

Pilot StudyPreliminary evidence
The takeaway

A nationwide pilot study found strong demand for cannabis use disorder treatment among women with MS, highlighting that over half of MS patients use cannabis and up to 20% may develop use disorder.

MS patients using cannabis, neurologists, addiction treatment specialists working with MS populations

Over 50% of MS patients use cannabis; up to 20% at risk for use disorder

What the researchers found

More than half of individuals with MS use cannabis, with up to 20% at risk for cannabis use disorder. While some report symptom relief (pain, sleep, mood), long-term use has been associated with poorer cognitive and emotional functioning, fatigue, and reduced quality of life. The pilot study's recruitment revealed significant demand for accessible interventions, highlighting an urgent unmet need.

Why it matters

MS patients who use cannabis often fall into a treatment gap: their neurologists may not screen for problematic use, and addiction specialists may not understand MS-specific considerations. This pilot study documents the demand for integrated treatment approaches.

The numbers in context

Over 50% of MS patients use cannabis. Up to 20% at risk for CUD. Cannabis associated with poorer cognitive functioning, fatigue, and reduced quality of life in long-term MS users. Benefits reported for pain, sleep, and mood. Significant recruitment demand for the intervention.

How the study worked

Nationwide pilot study recruiting women with MS and cannabis use disorder for a remotely supervised home-based intervention. The study report focuses on recruitment insights, cannabis use patterns, and the demand for treatment.

What this study cannot tell us

Pilot study focused on recruitment insights rather than outcomes. Women only. Cannot determine causation for the associations between long-term cannabis use and poorer MS outcomes. Self-selected population may not represent all MS patients with CUD.

How to read the evidence

Preliminary evidence from a pilot study focused on demonstrating need and feasibility rather than treatment outcomes.

When this study was published

2025 nationwide pilot study on cannabis use disorder in multiple sclerosis.

The bigger picture

The intersection of MS and cannabis use is increasingly relevant as medical cannabis becomes more accessible. While some MS patients benefit from cannabis for specific symptoms, the risk of developing use disorder and the association with worse cognitive outcomes creates a complex clinical picture that current treatment infrastructure does not adequately address.

Questions still open

  • How should neurologists screen for problematic cannabis use in MS patients? Would structured cannabis reduction programs improve cognitive outcomes in MS? Can medical cannabis be used therapeutically while preventing use disorder development?

Common questions

Is cannabis use disorder common in MS patients?
More than half of MS patients use cannabis, and up to 20% may develop cannabis use disorder. While some patients report benefits for pain, sleep, and mood, long-term use has been associated with worse cognitive function and quality of life.
Why is treatment for cannabis use disorder in MS lacking?
MS patients with cannabis use disorder fall between neurology and addiction medicine, with neither specialty typically addressing both conditions. This pilot study documented significant demand for integrated, accessible treatment, highlighting an urgent gap in care.

Read the original research

The unmet need for cannabis use disorder treatment in multiple sclerosis: Insights from a nationwide pilot study.

Multiple sclerosis and related disorders, 98, 106443

Citation

Pilloni, Giuseppina; Pehel, Shayna; Ko, Timothy; Kreisberg, Erica; Sammarco, Carrie; Charlson, R Erik; Charvet, Leigh. (2025). The unmet need for cannabis use disorder treatment in multiple sclerosis: Insights from a nationwide pilot study.. Multiple sclerosis and related disorders, 98, 106443. https://doi.org/10.1016/j.msard.2025.106443

Explore the wider topic